In conclusion, the present findings reveal that some mutations found in human cancers do not alter Smad4 function but rather inhibit TGF-β signaling by enhancing GSK3 phosphorylation of Smad4, which leads to its subsequent degradation. This evidence concerns the gene SMAD4 and cancer.